FERNANDEZ ARANCIBIA, MARIO
Thumbnail Image
Preferred name
FERNANDEZ ARANCIBIA, MARIO
Main Affiliation
Email
mariofernandez@udd.cl
ORCID
Scopus Author ID
7403378256

Research Output

2024 2024 2023 2023 2022 2022 2021 2021 2020 2020 2019 2019 2018 2018 2017 2017 2016 2016 2015 2015 0.0 0.0 0.5 0.5 1.0 1.0 1.5 1.5 2.0 2.0 2.5 2.5 3.0 3.0 3.5 3.5 4.0 4.0

Filters

1 1
Reset filters

Settings
Now showing 1 - 10 of 35
No Thumbnail Available
Publication

Topical Chemotherapy in Human Urothelial Carcinoma Explants: A Novel Translational Tool for Preclinical Evaluation of Experimental Intravesical Therapies

2009 , Christian Bolenz , Eva-Maria Ikinger , Philipp Ströbel , Lutz Trojan , Annette Steidler , FERNANDEZ ARANCIBIA, MARIO , Patrick Honeck , Ute Gabriel , Christel Weiss , Rainer Grobholz , Peter Alken , Maurice Stephan Michel

View
No Thumbnail Available
Publication

Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration

2009 , Nicholas J. Hellenthal , Shahrokh F. Shariat , Vitaly Margulis , Pierre I. Karakiewicz , Marco Roscigno , Christian Bolenz , Mesut Remzi , Alon Weizer , Richard Zigeuner , Karim Bensalah , Casey K. Ng , Jay D. Raman , Eiji Kikuchi , Francesco Montorsi , Mototsugu Oya , Christopher G. Wood , FERNANDEZ ARANCIBIA, MARIO , Christopher P. Evans , Theresa M. Koppie

View
No Thumbnail Available
Publication

Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract

2010 , Richard Zigeuner , Shahrokh F. Shariat , Vitaly Margulis , Pierre I. Karakiewicz , Marco Roscigno , Alon Weizer , Eiji Kikuchi , Mesut Remzi , Jay D. Raman , Christian Bolenz , Karim Bensalah , Umberto Capitanio , Theresa M. Koppie , Wassim Kassouf , Kanishka Sircar , Jean-Jacques Patard , FERNANDEZ ARANCIBIA, MARIO , Christopher G. Wood , Francesco Montorsi , Philipp Ströbel , Jeffery C. Wheat , Andrea Haitel , Mototsugu Oya , Charles C. Guo , Casey Ng , Daher C. Chade , Arthur Sagalowsky , Cord Langner

View
No Thumbnail Available
Publication

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer

2019 , FERNANDEZ ARANCIBIA, MARIO , Maurizio Brausi , Peter E. Clark , Michael S. Cookson , H. Barton Grossman , Makarand Khochikar , Lambertus A. Kiemeney , Bernard Malavaud , Rafael Sanchez-Salas , Mark S. Soloway , Robert S. Svatek , Raghunandan Vikram , Alina Vrieling , Ashish M. Kamat

View
No Thumbnail Available
Publication

Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer

2009 , Marco Roscigno , Shahrokh F. Shariat , Massimo Freschi , Vitaly Margulis , Pierre Karakiewizc , Nazareno Suardi , Mesut Remzi , Richard Zigeuner , Christian Bolenz , Eiji Kikuchi , Alon Weizer , Karim Bensalah , Arthur Sagalowsky , Theresa M. Koppie , Jay Raman , FERNANDEZ ARANCIBIA, MARIO , Philipp Ströbel , Wareef Kabbani , Cord Langner , Jeffery Wheat , Charles C. Guo , Wassim Kassouf , Andrea Haitel , Christopher G. Wood , Francesco Montorsi

View
No Thumbnail Available
Publication

Immediate postoperative morbidity in patients with indwelling double-J stent versus overnight-externalized ureteral catheter after tubeless percutaneous nephrolithotomy: a prospective, randomized study

2013 , Alejandro Mercado , FERNANDEZ ARANCIBIA, MARIO , Pedro Recabal , Daniela Fleck , Rodrigo Ledezma , Francisco Moya , Francisco Sepúlveda , Roberto Vilches , Diego Reyes , Fernando Marchant

View
No Thumbnail Available
Publication

A prospective randomized study comparing bipolar plasmakinetic transurethral resection of the prostate and monopolar transurethral resection of the prostate for the treatment of Benign Prostatic Hyperplasia: efficacy, sexual function, Quality of Life, and complications

2021 , Hugo Otaola-Arca , Manuel Álvarez-Ardura , Roberto Molina-Escudero , FERNANDEZ ARANCIBIA, MARIO , Álvaro Páez-Borda

View
No Thumbnail Available
Publication

Implementación de los nuevos tratamientos para el tumor vesical no músculo invasivo que no responde al tratamiento con BCG. Aspectos a considerar en Latinoamérica

2024 , FERNANDEZ ARANCIBIA, MARIO

View
No Thumbnail Available
Publication

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

2016 , Francesco Soria , Shahrokh F. Shariat , Seth P. Lerner , Hans-Martin Fritsche , Michael Rink , Wassim Kassouf , Philippe E. Spiess , Yair Lotan , Dingwei Ye , FERNANDEZ ARANCIBIA, MARIO , Eiji Kikuchi , Daher C. Chade , Marko Babjuk , Arthur P. Grollman , George N. Thalmann

View
No Thumbnail Available
Publication

Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma

2009 , Eiji Kikuchi , Vitaly Margulis , Pierre I. Karakiewicz , Marco Roscigno , Shuji Mikami , Yair Lotan , Mesut Remzi , Christian Bolenz , Cord Langner , Alon Weizer , Francesco Montorsi , Karim Bensalah , Theresa M. Koppie , FERNANDEZ ARANCIBIA, MARIO , Jay D. Raman , Wassim Kassouf , Christopher G. Wood , Nazareno Suardi , Mototsugu Oya , Shahrokh F. Shariat

To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). Patients and Methods Data were collected on 1,453 patients treated with RNU at 13 academic centers and combined into a relational database. Pathologic slides were rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence of tumor cells within an endothelium-lined space. Results LVI was observed in 349 patients (24%). Proportion of LVI increased with advancing tumor stage, high tumor grade, presence of tumor necrosis, sessile tumor architecture, and presence of lymph node metastasis (all P < .001). LVI was an independent predictor of disease recurrence and survival (P < .001 for both). Addition of LVI to the base model (comprising pathologic stage, grade, and lymph node status) marginally improved its predictive accuracy for both disease recurrence and survival (1.1%, P = .03; and 1.7%, P < .001, respectively). In patients with negative lymph nodes and those in whom a lymphadenectomy was not performed (n = 1,313), addition of LVI to the base model improved the predictive accuracy of the base model for both disease recurrence and survival by 3% (P < .001 for both). In contrast, LVI was not associated with disease recurrence or survival in node-positive patients (n = 140). Conclusion LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC.

View